Volume 14, Issue 5 pp. 341-349
Original Article

Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study

Cecilia Andersson

Corresponding Author

Cecilia Andersson

Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden

Corresponding author: Cecilia Andersson,

Department of Clinical Sciences,

Lund University/CRC,

Jan Waldenströms gata 35,

Skåne University Hospital SUS,

SE-20502 Malmö,

Sweden.

Tel: +46 40 39 11 12;

fax: +46 40 39 19 19;

e-mail: [email protected]

Search for more papers by this author
Annelie Carlsson

Annelie Carlsson

Department of Paediatrics, Lund University, Skåne University Hospital SUS, Lund, Sweden

Search for more papers by this author
Corrado Cilio

Corrado Cilio

Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden

Search for more papers by this author
Elisabeth Cedervall

Elisabeth Cedervall

Department of Paediatrics, Helsingborg Hospital, Helsingborg, Sweden

Search for more papers by this author
Sten-Anders Ivarsson

Sten-Anders Ivarsson

Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden

Search for more papers by this author
Berglind Jonsdottir

Berglind Jonsdottir

Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden

Search for more papers by this author
Björn Jönsson

Björn Jönsson

Department of Paediatrics, Ystad Hospital, Ystad, Sweden

Search for more papers by this author
Karin Larsson

Karin Larsson

Department of Paediatrics, Kristianstad Hospital, Kristianstad, Sweden

Search for more papers by this author
Jan Neiderud

Jan Neiderud

Department of Paediatrics, Helsingborg Hospital, Helsingborg, Sweden

Search for more papers by this author
Åke Lernmark

Åke Lernmark

Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden

Search for more papers by this author
Helena Elding Larsson

Helena Elding Larsson

Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden

Search for more papers by this author
for the DiAPREV-IT study group

for the DiAPREV-IT study group

See Appendix.

Search for more papers by this author
First published: 08 March 2013
Citations: 12

Abstract

Aims

Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children.

Methods

In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8–65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were determined at fasting and during IvGTT and OGTT.

Results

All children aged median 5.1 (4.0–9.2) yr had autoantibodies to two to six of the beta-cell antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤30 μU/mL insulin) first-phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03).

Conclusion

Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.